Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Totus Medicines
BeOne Medicines
BeOne Medicines
"Oncostar" LLC
Novartis
EMD Serono
Regor Pharmaceuticals Inc.
Eli Lilly and Company
Pfizer
MOMA Therapeutics
Eli Lilly and Company
Eli Lilly and Company
Kivu Bioscience Inc.
AstraZeneca
BeOne Medicines
Incyte Corporation
Mersana Therapeutics
Cellectar Biosciences, Inc.
Eli Lilly and Company
Iambic Therapeutics, Inc
Nammi Therapeutics Inc
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
ExpreS2ion Biotechnologies
Boundless Bio, Inc.
Halda Therapeutics OpCo, Inc.
Novartis
Fate Therapeutics
Conjupro Biotherapeutics, Inc.
Conjupro Biotherapeutics, Inc.
Pfizer
Genentech, Inc.
Regor Pharmaceuticals Inc.
Cogent Biosciences, Inc.
GlaxoSmithKline
SystImmune Inc.
Orano Med LLC
Atavistik Bio, Inc
BioNTech SE
Pfizer
NiKang Therapeutics, Inc.
Genentech, Inc.
Eisai Inc.
TerSera Therapeutics LLC
Alterome Therapeutics, Inc.
Rovi Pharmaceuticals Laboratories
ViroMissile, Inc.
Eisai Inc.
Replimune, Inc.
Kind Pharmaceuticals LLC